Pfizer, Amgen eye $1B deal for Russian biosimilars developer Biocad

Russian pharma dealmaking is heating up. On the heels of news that Pharmastandard is shopping its over-the-counter business, the biosimilar developer Biocad is said to be entertaining offers from the likes of Pfizer and Amgen. The Russian company could be worth as much as $1 billion, sources told Bloomberg. Story

Suggested Articles

The biotech behind AstraZeneca and the University of Oxford’s late-stage pandemic vaccine has hired Margaret (Meg) Marshall, M.D., as its new CMO.

On the heels of a merger and $60 million private offering, Compass is looking to go public. It filed to raise up to $50 million in its Nasdaq IPO.

he results suggest V114 provides broader protection from pneumococcal bacteria than Prevnar 13 does, positioning Merck to muscle in on Pfizer’s turf.